Phosphatidylethanolamine-binding protein 4 deficiency exacerbates carbon tetrachloride-induced liver fibrosis by regulating the NF-κB signaling pathway
Open Access
- 2 September 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 964829
Abstract
Liver fibrosis is a pathological process which can progress to hepatocirrhosis, even hepatocellular carcinoma. Phosphatidylethanolamine-binding protein 4 (PEBP4) is a secreted protein involved in regulating many molecular pathways, whereas its roles in diseases including hepatic fibrosis remain undefined. The nuclear factor-κappa B (NF-κB) signaling pathway has been found to be involved in the development of liver fibrosis. In this study, we generated a hepatocyte-conditional knockout (CKO) mouse model of PEBP4, and explored the potential functions of PEBP4 on liver fibrosis and the NF-κB signaling pathway in a mouse model of carbon tetrachloride (CCl4)-induced liver fibrosis. We demonstrated that PEBP4 CKO aggravated CCl4-triggered liver fibrosis, as evidenced by altered histopathology, an increase in the activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and hydroxyproline (HYP) levels, and more collagen deposition, as well as by enhanced expression of fibrotic markers including α-smooth muscle actin (α-SMA), collagen I and collagen III. Mechanistically, PEBP4 deficiency activated the NF-κB signaling pathway, as indicated by increased phosphorylation of NF-κB p65 and inhibitor protein κB inhibitor-α (IκB-α), and nuclear NF-κB p65 expression in the fibrotic liver. Notably, the NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC) partially blocked the activation of the NF-κB pathway, and reversed the pro-fibrotic effect of PEBP4 deletion in CCl4-treated mice. Together, these results suggest that PEBP4 deficiency results in aggravation of liver fibrosis and activation of the NF-κB signaling pathway, supporting a novel concept that PEBP4 is a crucial player in hepatic fibrosis, but also might be a negative regulator of the NF-κB signaling in liver fibrosis.Keywords
Funding Information
- National Natural Science Foundation of China (81760117 81660163)
- Natural Science Foundation of Jiangxi Province (20181BAB205012)
This publication has 23 references indexed in Scilit:
- Phosphatidylethanolamine binding protein 4 (PEBP4) is a secreted protein and has multiple functionsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2016
- Phosphatidylethanolamine-binding protein 4 is associated with breast cancer metastasis through Src-mediated Akt tyrosine phosphorylationOncogene, 2013
- Pathogenesis of Liver FibrosisAnnual Review of Pathology: Mechanisms of Disease, 2011
- NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinomaNature Reviews Gastroenterology & Hepatology, 2011
- Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesisProceedings of the National Academy of Sciences, 2009
- Identification of Novel Molecular Candidates for Acute Liver Failure in Plasma of BALB/c Murine ModelJournal of Proteome Research, 2007
- Silencing of Human Phosphatidylethanolamine-Binding Protein 4 Sensitizes Breast Cancer Cells to Tumor Necrosis Factor-α–Induced Apoptosis and Cell Growth ArrestClinical Cancer Research, 2005
- Liver fibrosis – from bench to bedsideJournal of Hepatology, 2003
- Liver nbsp fibrosis signals leading to the amplification of the fibrogenic hepatic stellate cellFrontiers in Bioscience-Landmark, 2003
- HEPATIC FIBROSISClinics in Liver Disease, 2001